FDA expands use of remdesivir to patients with high risk of hospitalization

1 minute read

An ampule of Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS

Register now for FREE unlimited access to Reuters.com

Jan 21 (Reuters) - The U.S. health regulator on Friday expanded its approval for the use of Gilead Sciences' (GILD.O) antiviral drug remdesivir to treat non-hospitalized patients 12 years and older for the treatment of mild-to-moderate COVID-19 disease with high risk of hospitalization.

Previously, the use of Veklury was limited to patients requiring hospitalization.

Register now for FREE unlimited access to Reuters.com
Reporting by Leroy Leo in Bengaluru; editing by Diane Craft

Our Standards: The Thomson Reuters Trust Principles.